Kendra Sweet

10PUBLICATIONS
59CO-AUTHORS
Medical molecular engineering of nucleic acids and proteinsCancer therapy (excl. chemotherapy and radiation therapy)HaematologyBiologically active moleculesHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Feb 11, 2026
Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents.

Dimitrios Drekolias, Fatima Tuz Zahra, Caroline Fileni

|Aug 07, 2025
Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia.

Somedeb Ball, Akriti G Jain, Najla Al Ali

|Dec 02, 2024
Clinical perspectives on post-induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation.

Kendra Sweet, Thomas Cluzeau

|Jan 05, 2024
Project Confirm: Accelerated Drug Approvals for CML-Response.

Kendra L Sweet, Jorge E Cortes, Jane F Apperley

|Sep 14, 2023
Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemia.

Parth C Patel, Somedeb Ball, Akriti G Jain

|Dec 22, 2022
Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia.

Kendra L Sweet, Jorge E Cortes, Jane F Apperley

Pageof 2

Frequent Collaborators

6 joint publications

Jeffrey Lancet

6 joint publications

Rami S Komrokji

5 joint publications

Andrew T Kuykendall

5 joint publications

David Sallman